Cardiff Oncology shakes up leadership, touts Phase 2 trial

Cardiff Oncology reported major leadership changes and a clinical program update.

Rhea-AI Filing Summary

Cardiff Oncology reported major leadership changes and a clinical program update. On January 27, 2026, longtime CEO Dr. Mark Erlander and CFO James Levine stepped down as part of a strategic leadership review. The Board appointed director Dr. Mani Mohindru as interim CEO and promoted Brigitte Lindsay, previously Senior Vice President, Finance, to Chief Accounting Officer.

The company also highlighted a positive update from CRDF-004, a randomized Phase 2 trial of its drug candidate onvansertib combined with standard-of-care regimens in first-line RAS‑mutated metastatic colorectal cancer. Details of the results are provided in an attached press release, which is largely incorporated by reference into this report.

Insights

Biotech & governance analyst

Cardiff pairs CEO/CFO exits with a positive Phase 2 trial signal.

The company states that CEO Mark Erlander and CFO James Levine stepped down on January 27, 2026 as part of a “strategic leadership review.” The Board moved quickly to maintain continuity by naming director Mani Mohindru as interim CEO and elevating Brigitte Lindsay to Chief Accounting Officer. Dr. Mohindru brings prior CEO roles and capital markets and biotech research experience, which may help guide corporate strategy and financing.

At the same time, Cardiff drew attention to a “positive update” from CRDF-004, a randomized Phase 2 study of onvansertib in combination with standard regimens (FOLFIRI/bevacizumab or FOLFOX/bevacizumab) in first-line RAS‑mutated metastatic colorectal cancer. The report does not provide specific efficacy or safety figures; it instead incorporates the press release describing those results by reference. Overall, this filing combines potentially reassuring clinical progress with a meaningful leadership transition, and the ultimate significance will depend on the detailed trial data and future leadership decisions disclosed in subsequent reports.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership changes did Cardiff Oncology (CRDF) announce?

On January 27, 2026, Dr. Mark Erlander, CEO, and James Levine, CFO, stepped down from their roles as part of a strategic leadership review. The Board appointed Dr. Mani Mohindru as interim CEO and promoted Brigitte Lindsay to Chief Accounting Officer.

Who is the new interim CEO of Cardiff Oncology (CRDF)?

Dr. Mani Mohindru, previously a member of the Board of Directors, was appointed interim CEO. She is an experienced biotechnology executive, founder of Roshon Therapeutics, and has held CEO and senior leadership roles at several public biotech companies.

What new role was given to Brigitte Lindsay at Cardiff Oncology?

Brigitte Lindsay, formerly Senior Vice President, Finance, was promoted to Chief Accounting Officer, giving her expanded responsibility over the company’s accounting function.

What is the CRDF-004 clinical trial mentioned by Cardiff Oncology?

CRDF-004 is a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care regimens FOLFIRI/bevacizumab or FOLFOX/bevacizumab in patients with first-line RAS‑mutated metastatic colorectal cancer.

How did Cardiff Oncology describe the latest CRDF-004 results?

The company said it issued a press release on January 27, 2026 announcing a positive update from the CRDF-004 Phase 2 trial. Specific data are contained in the attached press release, which is incorporated by reference.

Where can investors find more detail on Cardiff Oncology’s leadership and trial update?

More detail is provided in two press releases attached as Exhibits 99.1 and 99.2 dated January 27, 2026, which cover the leadership changes and the positive CRDF-004 trial update.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 04:01 PM Learn about SEC filing dates

false000121303700012130372026-01-272026-01-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 27, 2026

Cardiff Oncology, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-35558	27-2004382
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
11055 Flintkote Avenue
San Diego, California				92121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 952-7570

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		CRDF		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 27, 2026, Dr. Mark Erlander, Ph.D., CEO of Cardiff Oncology, Inc. (the “Company”), and James Levine, CFO of the Company stepped down from their respective roles at the Company as part of a strategic leadership review. The Board of Directors of the Company has appointed Dr. Mani Mohindru, a member of the Company’s Board of Directors, as interim CEO of the Company. In addition, Brigitte Lindsay, the Company’s Senior Vice President, Finance has been promoted to Chief Accounting Officer.

Dr. Mohindru is an experienced biotechnology executive with leadership experience spanning drug development, corporate strategy, and capital markets. She is the founder of Roshon Therapeutics, a private biotechnology company focused on developing novel therapies for cancer and inflammatory diseases and currently serves on the Board of Directors of CytomX Therapeutics, Inc. (Nasdaq: CTMX). Previously, Dr. Mohindru served as Chief Executive Officer and Board Director of Novasenta and CereXis, and held senior leadership roles at public biotechnology companies including Cara Therapeutics, Inc. and Curis, Inc.

Earlier in her career, Dr. Mohindru was an equity research analyst covering the biotechnology sector at UBS, Credit Suisse, and ThinkEquity. She currently serves on the Executive Advisory Board of the CLP Institute at Northwestern University and the Scientific Investment Advisory Committee of the Gates Institute at the University of Colorado. Dr. Mohindru holds a PhD in Neurosciences from Northwestern University, as well as a BS in Human Biology and a Master’s degree in Biotechnology from the All India Institute of Medical Sciences in New Delhi, India.

A copy of the press release is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 8.01 Other Events.

On January 27, 2026, the Company issued a press release (the “Press Release”) announcing a positive update from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) regimens (FOLFIRI/bevacizumab(bev) or FOLFOX/bev) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). A copy of the press release is attached as Exhibit 99.2 hereto. The information in the Press Release, except for the information set forth in the third paragraph of the Press Release containing a quote by Dr. Mani Mohindru, interim Chief Executive Officer of the Company and the fourth paragraph of the Press Release containing a quote by Dr. J Randolph Hecht, MD, Professor of Clinical Medicine at the David Geffen School of Medicine at UCLA, is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1	Press Release of Cardiff Oncology, Inc. dated January 27, 2026.
99.2	Press Release of Cardiff Oncology, Inc. dated January 27, 2026.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CARDIFF ONCOLOGY, INC.
Date:	January 27, 2026	By:	/s/ Mani Mohindru
			Mani Mohindru Interim Chief Executive Officer

3